Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.
El Mundo on MSN22h
These are the 11 new best-selling drugs that will transform Medicine in 2025
The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...